These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display α-Synuclein Pathology and Abnormal Mitochondrial Morphology. Diao X; Wang F; Becerra-Calixto A; Soto C; Mukherjee A Cells; 2021 Sep; 10(9):. PubMed ID: 34572052 [TBL] [Abstract][Full Text] [Related]
3. Modeling Parkinson's disease using induced pluripotent stem cells. Byers B; Lee HL; Reijo Pera R Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490 [TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication. Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617 [TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease in a dish - Using stem cells as a molecular tool. Badger JL; Cordero-Llana O; Hartfield EM; Wade-Martins R Neuropharmacology; 2014 Jan; 76 Pt A():88-96. PubMed ID: 24035919 [TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein pathology is associated with astrocyte senescence in a midbrain organoid model of familial Parkinson's disease. Muwanigwa MN; Modamio-Chamarro J; Antony PMA; Gomez-Giro G; Krüger R; Bolognin S; Schwamborn JC Mol Cell Neurosci; 2024 Mar; 128():103919. PubMed ID: 38307302 [TBL] [Abstract][Full Text] [Related]
7. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. Byers B; Cord B; Nguyen HN; Schüle B; Fenno L; Lee PC; Deisseroth K; Langston JW; Pera RR; Palmer TD PLoS One; 2011; 6(11):e26159. PubMed ID: 22110584 [TBL] [Abstract][Full Text] [Related]
8. Cellular α-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons. Zambon F; Cherubini M; Fernandes HJR; Lang C; Ryan BJ; Volpato V; Bengoa-Vergniory N; Vingill S; Attar M; Booth HDE; Haenseler W; Vowles J; Bowden R; Webber C; Cowley SA; Wade-Martins R Hum Mol Genet; 2019 Jun; 28(12):2001-2013. PubMed ID: 30753527 [TBL] [Abstract][Full Text] [Related]
9. From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson's Disease Modeling and Regenerative Therapy. Yeap YJ; Teddy TJW; Lee MJ; Goh M; Lim KL Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768843 [TBL] [Abstract][Full Text] [Related]
11. Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications. Iannielli A; Luoni M; Giannelli SG; Ferese R; Ordazzo G; Fossati M; Raimondi A; Opazo F; Corti O; Prehn JHM; Gambardella S; Melki R; Broccoli V Cell Death Dis; 2022 Oct; 13(10):881. PubMed ID: 36261424 [TBL] [Abstract][Full Text] [Related]
12. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146 [TBL] [Abstract][Full Text] [Related]
13. Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson's disease. Brazdis RM; Alecu JE; Marsch D; Dahms A; Simmnacher K; Lörentz S; Brendler A; Schneider Y; Marxreiter F; Roybon L; Winner B; Xiang W; Prots I Hum Mol Genet; 2020 May; 29(7):1180-1191. PubMed ID: 32160287 [TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Devine MJ; Ryten M; Vodicka P; Thomson AJ; Burdon T; Houlden H; Cavaleri F; Nagano M; Drummond NJ; Taanman JW; Schapira AH; Gwinn K; Hardy J; Lewis PA; Kunath T Nat Commun; 2011 Aug; 2():440. PubMed ID: 21863007 [TBL] [Abstract][Full Text] [Related]
15. Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells. Kim MS; Kim H; Lee G Adv Healthc Mater; 2024 Aug; 13(21):e2303041. PubMed ID: 38269602 [TBL] [Abstract][Full Text] [Related]
16. Neural stem cells derived from human midbrain organoids as a stable source for treating Parkinson's disease: Midbrain organoid-NSCs (Og-NSC) as a stable source for PD treatment. Kim SW; Woo HJ; Kim EH; Kim HS; Suh HN; Kim SH; Song JJ; Wulansari N; Kang M; Choi SY; Choi SJ; Jang WH; Lee J; Kim KH; Lee W; Kim SH; Yang J; Kyung J; Lee HS; Park SM; Chang MY; Lee SH Prog Neurobiol; 2021 Sep; 204():102086. PubMed ID: 34052305 [TBL] [Abstract][Full Text] [Related]
17. Molecular Features of Parkinson's Disease in Patient-Derived Midbrain Dopaminergic Neurons. Ren Y; Jiang H; Pu J; Li L; Wu J; Yan Y; Zhao G; Guttuso TJ; Zhang B; Feng J Mov Disord; 2022 Jan; 37(1):70-79. PubMed ID: 34564901 [TBL] [Abstract][Full Text] [Related]
18. Single-Cell Transcriptomics of Parkinson's Disease Human In Vitro Models Reveals Dopamine Neuron-Specific Stress Responses. Fernandes HJR; Patikas N; Foskolou S; Field SF; Park JE; Byrne ML; Bassett AR; Metzakopian E Cell Rep; 2020 Oct; 33(2):108263. PubMed ID: 33053338 [TBL] [Abstract][Full Text] [Related]
19. High-content phenotyping of Parkinson's disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification. Vuidel A; Cousin L; Weykopf B; Haupt S; Hanifehlou Z; Wiest-Daesslé N; Segschneider M; Lee J; Kwon YJ; Peitz M; Ogier A; Brino L; Brüstle O; Sommer P; Wilbertz JH Stem Cell Reports; 2022 Oct; 17(10):2349-2364. PubMed ID: 36179692 [TBL] [Abstract][Full Text] [Related]
20. Optogenetic induction of alpha-synuclein aggregation in human dopaminergic neurons to model Parkinson's disease pathology. Ra EA; Kim MS; Lee G STAR Protoc; 2023 Dec; 4(4):102609. PubMed ID: 37742181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]